Evidence map›Paper›PMID 34807348›Full record

ArticleInternational urology and nephrology2022

Serum irisin is a novel biomarker for bladder cancer detection.

Kerem Taken, Rahmi Aslan, Recep Eryilmaz, Hamit Hakan Alp, Zübeyir Huyut, Muhammet İrfan Dönmez

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Serum irisin concentration in patients with bladder cancer.International urology and nephrology · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kerem TakenDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yıl University, 65080, Van, Turkey.
Rahmi AslanDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yıl University, 65080, Van, Turkey.
Recep EryilmazDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yıl University, 65080, Van, Turkey.
Hamit Hakan AlpDepartment of Medical Biochemistry, Faculty of Medicine, Van Yuzuncu Yıl University, 65080, Van, Turkey.
Zübeyir HuyutDepartment of Medical Biochemistry, Faculty of Medicine, Van Yuzuncu Yıl University, 65080, Van, Turkey.
Muhammet İrfan DönmezDepartment of Urology, İstanbul Faculty of Medicine, İstanbul University, İstanbul Tıp Fakültesi Cerrahi Monoblok, Fatih, 34093, İstanbul, Turkey. m_irfan83@yahoo.com.ORCID http://orcid.org/0000-0002-2828-7942
Van Yüzüncü Yıl Üniversitesi · TRIstanbul University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study intended to investigate irisin levels in bladder cancer patients and healthy controls.

objectiveOur aim was to evaluate if serum irisin could be used as a diagnostic tool in bladder cancer and further, if it could differentiate muscle-invasive and non-muscle-invasive bladder cancer patients.

methodsIn this study, 90 primary bladder cancer patients in addition to 30 age-matched healthy individuals for the control group were prospectively included. Bladder cancer patients were divided into two subgroups as non-muscle-invasive (60 patients) and muscle-invasive (30 patients). Blood samples were obtained before the diagnosis of the disease. Serum irisin levels were measured using ELISA. Demographic data as well as tumor grade and stage were noted.

resultsMean serum irisin level was significantly lower in the bladder cancer patients compared to the control group (4.53 ± 2.55 vs. 16.5 ± 5.67, p < 0.001). Also, serum irisin level was statistically lower in the muscle-invasive bladder cancer group compared to the non-muscle-invasive counterparts (3.19 ± 1.47 vs. 5.18 ± 2.73, p < 0.001). Serum irisin could differentiate bladder cancer patients from healthy individuals with a sensitivity of 86.2% and a specificity of 89.7% at a cut-off value of 8.689 (AUC = 0.859). Moreover, to discriminate between NMIBC and MIBC, the sensitivity was 75% and the specificity was 73.7% at a cut-off value of 3.97 (AUC = 0.732).

conclusionOur results showed that serum irisin levels can be used for the diagnosis of bladder cancer. Also, it can help distinguish high-grade and stage tumor.

Indexed as

AgedBiomarkers, TumorDiagnosis, DifferentialFemaleFibronectinsHumansMaleMiddle AgedNeoplasm InvasivenessProspective StudiesUrinary Bladder NeoplasmsBiomarkers, TumorFibronectinsFNDC5 protein, humanBiomarkerBladder cancerDiagnosis, hematuriaIrisin

Identifiers

PMID34807348
OpenAlexW3216954151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.